Spectrum Pharmaceuticals, Inc. (Nasdaq:SPPI) today reported financial results for the third quarter ended September 30, 2007. The Company incurred a third quarter of 2007 net loss of approximately $7.4 million, or ($0.24) per basic and diluted share, compared to a net loss of approximately $7.4 million, or ($0.30) per share in the third quarter of 2006. Revenue in the third quarter of 2007 included $3.2 million in milestone payments from GPC Biotech. Research and development expenses were approximately $6.8 million in the third quarter 2007, compared to approximately $5.8 million in the third quarter of 2006, due to the expanded scope of the Company’s clinical development activities. General and administrative expenses were approximately $2.4 million in the third quarter of 2007, compared to approximately $1.5 million in the third quarter 2006, primarily due to legal expenses. As of October 31, 2007, approximately 31.2 million shares were issued and outstanding.
